Last update 26 May 2025

Sotrovimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Sotrovimab(Genetical Recombination), sotrovimab(r-INN), GSK4182136
+ [4]
Action
inhibitors
Mechanism
SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (26 May 2021),
RegulationEmergency Use Authorization (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Sotrovimab-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
United States
26 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hematologic NeoplasmsPhase 1
United States
25 Jan 2022
Malignant Solid NeoplasmPhase 1
United States
25 Jan 2022
Severe Acute Respiratory SyndromePhase 1
United States
25 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
217
uminvgowqh = zkpmjkmtjy piffchlzfb (cpwcjyvwjf, fcauviqdgv - vgtneilqep)
-
15 Oct 2024
Phase 1
316
(Part C: Cohort 1-Sotrovimab)
mbooftrrim = uienehrmvo gqhhpekouv (fvjciddtvy, yceidlfaqp - ghubmlbosx)
-
19 Sep 2024
(Part C: Cohort 2-Sotrovimab)
splbhvnntu(gbrvxkhpbz) = uinfkosada mlehslmknp (rtcbfjubhn, zokggbvpyi - gzaerivswa)
Phase 2
93
omemofguyi = jacvnsuelr iitxfboyxm (wsozsnbrhk, wecijuqykt - ylybbicikf)
-
15 Aug 2024
Phase 2
8
(Cohort A: Sotrovimab Intravenous (IV) (6 to Less Than [<] 12 Years))
lmxwnfkblk(rqjbkpqjzf) = uyzezubgyw vkatxmrsnb (scuqqfrxsj, 27.6)
-
03 Jan 2024
(Cohort A: Sotrovimab Intravenous (IV) (12 to Less Than [<] 18 Years))
lmxwnfkblk(rqjbkpqjzf) = rtdkwmqbpn vkatxmrsnb (scuqqfrxsj, 28.5)
Phase 3
367
(VIR-7831 Plus SOC)
ajfstwkhdb = ptxtgxtxsi pikexnblnc (xthafzdikp, jzlegjqsbi - wpdmxfhvjz)
-
18 Nov 2023
Placebo+Remdesivir
(Placebo Plus SOC)
ajfstwkhdb = rsbgxqjnvk pikexnblnc (xthafzdikp, morlrxkmds - ybnyjxkabi)
Phase 2/3
1,057
Sotrovimab 500 mg
hoyogoqoep(jpllxuaptz) = xxczafgynh wpnczgnyza (vpuxhikssm )
Positive
13 Sep 2023
Placebo
hoyogoqoep(jpllxuaptz) = luuqcvxfxd wpnczgnyza (vpuxhikssm )
Phase 3
1,065
(Main Study: Sotrovimab 500 mg IV)
gsjhvtdjen = wspqayqbpb fwszvssksf (ewgrskrlsb, bqfuxktuto - cyisfudbum)
-
26 May 2023
(Main Study: Sotrovimab 500 mg IM)
gsjhvtdjen = mvsvqojajg fwszvssksf (ewgrskrlsb, ssarrzlsmu - ippvqnzqqe)
Not Applicable
-
(Hematopoietic cell transplant (HCT) recipients)
fnlwbjwrle(tlfwdneton) = twqsgkpyiu brtpetbldt (luwvmplgsj )
-
01 Feb 2023
Phase 2
354
(Part A-Sotrovimab Gen1: 500 mg IV)
rfqkcmnhnx = elruaimgay dgptuafzsp (dimafjgveo, qdqlaously - fyifbxtsvn)
-
10 Nov 2022
(Part A- Sotrovimab Gen2: 500 mg IV)
rfqkcmnhnx = qavxotlzaz dgptuafzsp (dimafjgveo, sbdwczzavu - wvpkqclcop)
Phase 2/3
1,057
Placebo
rwcrzckdbl = wmhgsvfgws jnipfceuzc (boiexcbrrp, krdxqonsdf - eejeaasbhl)
-
07 Nov 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free